{"id":"rivastigmine-5-cm-2-transdermal-patch","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Dizziness"},{"rate":"5-10","effect":"Application site erythema"},{"rate":"2-5","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By blocking the breakdown of acetylcholine, a neurotransmitter critical for memory and cognition, rivastigmine increases its availability in the central nervous system. This is particularly beneficial in Alzheimer's disease where acetylcholine-producing neurons degenerate. The transdermal patch formulation provides sustained drug delivery over 24 hours, improving tolerability compared to oral dosing.","oneSentence":"Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase enzymes, increasing acetylcholine levels in the brain to improve cognitive function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:27.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Mild to moderate Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT00428389","phase":"PHASE3","title":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":262},{"nctId":"NCT00423085","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":859},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00506415","phase":"PHASE3","title":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":1584},{"nctId":"NCT00623103","phase":"PHASE3","title":"Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Parkinson's Disease Dementia","enrollment":583},{"nctId":"NCT00622713","phase":"PHASE4","title":"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Alzheimer's Disease","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rivastigmine 5 cm^2 transdermal patch","genericName":"Rivastigmine 5 cm^2 transdermal patch","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine is used to treat Alzheimer's Disease, Alzheimer Disease, and Parkinson's Disease Dementia, as indicated by ClinicalTrials.gov. The transdermal patch is available in various strengths, including 4.6 mg/24 h, 9.5 mg/24 h, and 13.3 mg/24 h, delivered through patches of different sizes, such as 5 cm^2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}